Pfizer has completed its acquisition of Biohaven Pharmaceutical, including Biohaven’s intranasal zavegepant (BHV-3500) calcitonin gene-related peptide (CGRP) receptor antagonist, the company said. Pfizer announced that it had acquired the ex-US rights to zavegepant and Nurtec ODT rimegepant from Biohaven January 2022. By the time that the FDA accepted Biohaven’s NDA for zavegepant for the treatment of migraine in May 2022, Pfizer had announced that it would acquire the company.
Pfizer Executive VP, Chief Business Innovation Officer, Aamir Malik commented, “We are proud to build on Pfizer’s legacy of delivering breakthrough medicines for patients living with complex pain disorders. The success of Nurtec ODT coupled with Biohaven’s CGRP pipeline will strengthen Pfizer’s innovative Internal Medicine pipeline through 2030, and beyond. Combined with Pfizer’s global reach, this acquisition increases our potential to bring new treatment options to patients with migraine – a disease which affects over 1 billion people worldwide.”
Read the Pfizer press release.
